ACT标准化监测流程在ECMO患者肝素抗凝中的应用研究

Abstract
Figure/Table
References (12)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application value of the standardized monitoring process of activated coagulation time (ACT) in heparin anticoagulation in patients with extracorporeal membrane oxygenation (ECMO). Methods A total of 46 patients who underwent ECMO treatment in the intensive care unit of our hospital from January 2019 to December 2020 were selected，according to different treatment methods, they were divided into study group (30 cases) and control group (16 cases). The two groups of patients were given heparin during the ECMO process. The control group used the conventional ACT monitoring method, and the study group used the ACT standardized monitoring process on the basis of the control group. The service life of the membrane lung, the probability of successful withdrawal, the survival rate within 3 months, the degree of coagulation of the membrane lung, pump and pipeline, and the degree of unfavorable bleeding between the two groups of patients were compared. Results The service life of the membrane lung in the study group was longer than that in the control group, and the successful weaning rate and survival rate within 3 months were higher than those in the control group, the differences were statistically significant (P＜0.05). The degree of coagulation of the membrane lung, pump and pipeline in the study group were better than those of the control group,the differences were statistically significant (P＜0.05). The degree of bleeding in the study group was better than that of the control group, and the difference was statistically significant (P＜0.05). Conclusion The application of ACT standardized monitoring process to ECMO patients can make heparin achieve the best anticoagulation state, improve the degree of blood coagulation, reduce the occurrence of adverse bleeding, there by effectively increasing the patient′s successful withdrawal rate and survival rate within 3 months, it has a high clinical application value.

Key words： Activated clotting time Standardization Extracorporeal membrane oxygenation Heparin Anticoagulation

Received: 29 April 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEI Ling

Cite this article:

WEI Ling. Application of ACT standardized monitoring process in ECMO patients with heparin anticoagulation[J]. 中国当代医药, 2021, 28(35): 47-49转53.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/47

[1]	张本，唐庆龙.ECMO 在重症创伤患者中的应用现状[J].华南国防医学杂志，2020，34（4）：292-295.
[2]	季艳梅，黄云飞，陈伟，等.阿加曲班与普通肝素在重度心肺功能不全患者体外膜肺氧合治疗中的抗凝比较及临床评价[J].山西医药杂志，2019，48（10）：1155-1158.
[3]	刘伟，卢帝君，王旭东，等.体外膜肺氧合心肺复苏的凝血特点及抗凝挑战[J].中国临床医生杂志，2020，48（9）：1017-1020.
[4]	曾义.浅析ACT 监测冠心病患者介入手术后抗凝剂应用的临床观察[J].中国医疗设备，2019，34（S1）：47-48.
[5]	尹小雪，刘德林，刘远，等.活化凝血时间和活化部分凝血活酶时间在成人体外膜肺氧合支持期间抗凝的作用探讨[J].中国体外循环杂志，2019，17（1）：18-21.
[6]	王瑜亮，王琦，张杨杨，等.体外膜肺氧合中血液异物界面作用对凝血的影响与对策[J].中国体外循环杂志，2019，17（1）：18-21
[7]	黄晓婧，赵红卫，马永成，等.低剂量普通肝素用于ECMO辅助支持患者抗凝治疗的系统评价[J].外科研究与新技术，2017，6（2）：113-117.
[8]	]魏秀娟，邵艳玲.肝素抗凝在ECMO 支持患者中的监测与护理进展[J].当代护士，2018，25（15）：31-33.
[9]	万鸿.规范血液采集程序提高血液检验质量[J].临床医药文献电子杂志，2020，7（21）：36.
[10]	杨会兰.肝素结合蛋白在肺炎并发脓毒症早期诊断中的价值[J].中国当代医药，2019，26（12）：64-66.
[11]	朱忠勇.凝血酶原时间和活化部分凝血活酶时间测定标准化(附纤维蛋白原测定推荐方法和淘汰过时的出凝血时间的建议)[J].中华医学检验杂志，1998（5）：51-55.
[12]	玛丽亚·巴拉提.凝血检测中护理人员操作的重要性分析[J].世界最新医学信息文摘，2019，19（40）：274-275.